Author:
Singh Rima,Nandave Mukesh,Kumar Anoop,Pandita Deepti
Publisher
Springer Nature Singapore
Reference36 articles.
1. Agrawal P (2014) Drug discovery and development: an insight into pharmacovigilance. J Pharmacovigil 2(3):120
2. Almenoff JS (2007) Innovations for the future of pharmacovigilance. Drug Saf 30:631–633
3. Amiri A, Okai J, Bahri P, Sarinić VM (2021) The fundamental value of exposure data for pharmacovigilance: review of different aggregation levels of exposure data in pharmaceutical companies’ PSURs. Drug Saf 44:1402–1402
4. Arlett P, Portier G, De Lisa R, Blake K, Wathion N, Dogne JM, Spooner A, Raine J, Rasi G (2014) Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee. Nat Rev Drug Discov 13(5):395–397
5. Arora D (2012) Pharmacovigilance—an industry perspective. Pharmapublisher, Navi Mumbai